About Surmodics, Inc
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The Vitro Diagnostics segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota. Address: 9924 West 74th Street, Eden Prairie, MN, United States, 55344
Surmodics, Inc News and around…
Latest news about Surmodics, Inc (SRDX) common stock and company :
Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.
SurModics (SRDX) delivered earnings and revenue surprises of 31.25% and 6.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Surmodics (NASDAQ:SRDX) reported its Q2 earnings results on Wednesday, April 27, 2022 at 07:30 AM. Here's what ...
Surmodics Reports Second Quarter Fiscal 2022 Results
Pounce™ Thrombectomy System First-in-Human Data Show 100 Percent Technical Success in Early Cases
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is projected to report earnings for its first ...
Dr. Gary Ansel to Present Pounce™ Thrombectomy System First-in-Human Data at Charing Cross Symposium
Surmodics (NASDAQ:SRDX) will host a conference call at 08:30 AM ET on April 27, 2022, to discuss Q2 2022 earnings results. How to ...
Surmodics to Webcast Second Quarter Fiscal 2022 Earnings Conference Call on April 27.
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Russell 2000—Dynamic Multifactor ETF (OMFS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $44.69 per unit.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco S&P SmallCap Health Care ETF (PSCH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $225.32 per unit.
Surmodics to Host Virtual Annual Meeting of Shareholders on February 10, 2022 at 4:00 p.m. (CT)
In the past three years, the share price of Surmodics, Inc. ( NASDAQ:SRDX ) has struggled to grow and now shareholders...
Gainers SOC Telemed (NASDAQ:TLMD) shares increased by 333.5% to $2.79 during Thursday's regular session. Trading ...
On Thursday, 105 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows And ...
SurModics (SRDX) delivered earnings and revenue surprises of 63.89% and 3.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Surmodics (NASDAQ:SRDX) reported its Q1 earnings results on Thursday, February 3, 2022 at 07:30 AM. Here's what ...
Surmodics Reports First Quarter Fiscal 2022 Results
Companies Reporting Before The Bell • Tuesday Morning (NASDAQ:TUEM) is likely to report earnings for its second ...
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Surmodics to Webcast First Quarter Fiscal 2022 Earnings Conference Call on February 3. Webcast is Live at 7:30 a.m. (CT)
* Presentation Times and Weblinks Released for Over 70 Presenting Companies * Wednesday and Thursday, January 19th-20th, 2022NEW YORK, NY / ACCESSWIRE / January 18, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Small Cap Virtual Conference taking place Wednesday and Thursday, January 19th-20th, 2022. The links can also be found at www.
Surmodics to Present at Sidoti & Company Virtual Investor Conference on January 19, 2022.
EDEN PRAIRIE, Minn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced the expansion of the board and appointment of two new board members: Lisa Wipperman Heine and William P. Burke. "I am thrilled to welcome Lisa and Bill to the Miromatrix Board as we continue developing bioengineered organs to address the transpla
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Surmodics (NASDAQ:SRDX) has had a rough month with its share price down 12%. It seems that the market might have...
SRDX earnings call for the period ending September 30, 2021.
Surmodics, Inc (SRDX) is a NASDAQ Common Stock listed in Common Stock, Diagnostics & Research, Healthcare
